Back to Search
Start Over
Blood levels of adiponectin and IL-1Ra distinguish type 3c from type 2 diabetes: Implications for earlier pancreatic cancer detection in new-onset diabetes.
- Source :
-
EBioMedicine [EBioMedicine] 2022 Jan; Vol. 75, pp. 103802. Date of Electronic Publication: 2022 Jan 03. - Publication Year :
- 2022
-
Abstract
- Background: Screening for pancreatic ductal adenocarcinoma (PDAC) in populations at high risk is recommended. Individuals with new-onset type 2 diabetes mellitus (NOD) are the largest high-risk group for PDAC. To facilitate screening, we sought biomarkers capable of stratifying NOD subjects into those with type 2 diabetes mellitus (T2DM) and those with the less prevalent PDAC-related diabetes (PDAC-DM), a form of type 3c DM commonly misdiagnosed as T2DM.<br />Methods: Using mass spectrometry- and immunoassay-based methodologies in a multi-stage analysis of independent sample sets (n=443 samples), blood levels of 264 proteins were considered using Ingenuity Pathway Analysis, literature review and targeted training and validation.<br />Findings: Of 30 candidate biomarkers evaluated in up to four independent patient sets, 12 showed statistically significant differences in levels between PDAC-DM and T2DM. The combination of adiponectin and interleukin-1 receptor antagonist (IL-1Ra) showed strong diagnostic potential, (AUC of 0.91; 95% CI: 0.84-0.99) for the distinction of T3cDM from T2DM.<br />Interpretation: Adiponectin and IL-1Ra warrant further consideration for use in screening for PDAC in individuals newly-diagnosed with T2DM.<br />Funding: North West Cancer Research, UK, Cancer Research UK, Pancreatic Cancer Action, UK.<br />Competing Interests: Declaration of Competing Interest LO, EC, WG, CH and PG are named as inventors on GB patent GB1806002.0; PCT/GB2019/050998, submitted by the University of Liverpool, that covers the measurement of adiponectin and IL-1Ra as a biomarker for early detection of pancreatic cancer. UM holds patent number EP EP10178345.4 for breast cancer diagnosis, and has stock ownership awarded by the University College London (UCL) in Abcodia.<br /> (Crown Copyright © 2021. Published by Elsevier B.V. All rights reserved.)
Details
- Language :
- English
- ISSN :
- 2352-3964
- Volume :
- 75
- Database :
- MEDLINE
- Journal :
- EBioMedicine
- Publication Type :
- Academic Journal
- Accession number :
- 34990893
- Full Text :
- https://doi.org/10.1016/j.ebiom.2021.103802